Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Influenza Vaccine in Myeloid Malignancy
NCT04484532Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2017
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of influenza virus vaccine, split virion in influenza, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Antibody response to influenza vaccination. Started Oct 2017; status: completed.
02
Drugs
influenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04484532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484532.